TLGS services & expertise · Curated intelligence
Healthcare, Pharma & Life Sciences is a critical pillar of India's economy and social infrastructure, overseen by the Ministry of Health & Family Welfare, Ministry of Chemicals & Fertilizers (Pharma division), and NITI Aayog. India is the world's largest supplier of generic medicines, supplying over 20% of global generic drug exports, while domestic health infrastructure is being scaled through Ayushman Bharat and the National Health Mission. Policy direction focuses on universal health coverage, PLI-driven pharma manufacturing, and positioning India as a global hub for medical devices and biologics.
Bharat Pulse · Enterprise intelligence · 17 September 2026
Policy developments translated into commercial implications, decisions and practical next steps.
For large enterprises, rate changes, exemptions and process reform become material through credit treatment, contracts, master data and the quality of the compliance record.
Effective framework · further process-reform watch
Read the brief & business implications →Reviewed 17 September 2026Bharat Pulse · TLGS Research · 2026-09-15
Official-source facts and TLGS perspectives, separated by status. An announced project is not an open bid; consultancy fees are distinct from the value of the underlying project.
Prepared research edition. Advertised notices require current issuer, corrigendum and award-status checks. This is not an exhaustive live procurement feed or a statement that TLGS is retained on these projects.
Union Budget 2026–27 announced Biopharma SHAKTI with an outlay of ₹10,000 crore over five years.
Healthcare, Pharma & Life Sciences · Manufacturing, MSME & Industrial Policy · Education & Skills
Read the brief & official sources →CDSCO’s public-notice list carries a 5 September 2026 item on coordinated action against illegal manufacture and distribution of misbranded drugs.
Healthcare, Pharma & Life Sciences · Manufacturing, MSME & Industrial Policy · Governance & Admin
Read the brief & official sources →CDSCO’s register includes August 2026 pendency statements uploaded in early September, including a West Zone publication dated 8 September.
Healthcare, Pharma & Life Sciences · Manufacturing, MSME & Industrial Policy · Governance & Admin
Read the brief & official sources →UK guidance published on 4 September 2026 records that CETA entered into force on 15 July 2026. It also sets India’s graduation from the UK’s DCTS for 15 July 2028.
Trade, Customs & Strategic Supply Chains · Manufacturing, MSME & Industrial Policy · Healthcare, Pharma & Life Sciences · Agriculture, Food Processing & Rural Economy · Financial Services, Capital Markets & Insurance
Read the brief & official sources →EFTA records TEPA entering into force on 1 October 2025. The participating EFTA states are Iceland, Liechtenstein, Norway and Switzerland. Its investment-mobilisation objectives are long-term goals, not automatic funding entitlements.
Trade, Customs & Strategic Supply Chains · Manufacturing, MSME & Industrial Policy · Financial Services, Capital Markets & Insurance · Healthcare, Pharma & Life Sciences · Power, Energy & Renewables
Read the brief & official sources →The European Commission’s agreements page records conclusion of EU–India FTA negotiations on 27 January 2026. That statement alone does not establish entry into force.
Trade, Customs & Strategic Supply Chains · Manufacturing, MSME & Industrial Policy · Healthcare, Pharma & Life Sciences · Agriculture, Food Processing & Rural Economy · Financial Services, Capital Markets & Insurance
Read the brief & official sources →Our work · Institutional client
TLGS is a long-standing pan-India regulatory advisory and operational-compliance partner to Tata 1mg, supporting defined assignments across retail pharmacy, e-pharmacy, institutional healthcare and e-diagnostics.
Explore the engagement →Sector experience · TLGS Our Work
Strategic advisory connecting a digital-health enterprise’s consumer, corporate and institutional channels with partnership design, governance and regulatory positioning.
Market-development & institutional structuringChallenge, solution & delivery →TLGS expertise
Former CMD, NSIC & NSIC Venture Capital Fund
Regional President — Chennai / South India
Chair, South India Enterprise Desk
Former CMD and board-level leader of NSIC and NSIC Venture Capital Fund, bringing MSME, enterprise-development and growth-finance experience.
View profileFormer Senior Director, Tata Consultancy ServicesIndependent-director and Risk Management Committee chair experience, Dr Lal PathLabs
Director & Practice Chair
Corporate Governance, Risk, Digital Strategy & Board Advisory
Board and strategy professional with experience in corporate governance, risk oversight, technology commercialisation and healthcare.
View profileFormer Assistant Commissioner, Food and Drugs Administration, Maharashtra State
Regional Principal Advisor
Pharmaceutical Regulatory Affairs, Licensing & Compliance (Maharashtra)
Former Assistant Commissioner, FDA Maharashtra, with more than three decades of experience in pharmaceutical regulation, licensing, inspections, quality systems and regulatory administration.
View profileRegional Lead
UAE & Middle East Business Operations
Consulting and business-analysis professional with experience in healthcare initiatives, MSME policy, technology and cross-border coordination.
View profileBharat Pulse Dialogues
Explore related interactions, institutional experience and our wider editorial perspective.
Bharat Pulse DialoguesHealth, Agriculture & Inclusion
Minister of State (Independent Charge), Government of Uttar Pradesh
Horticulture, Agricultural Marketing, Agricultural Foreign Trade & Agricultural Exports
An interaction with Dr. Karan Garg
Read the interaction
Bharat Pulse DialoguesHealth, Agriculture & Inclusion
Board Member, Sevaro Health
Sevaro Health
An interaction with Dr. Karan Garg
Read the interaction
Bharat Pulse DialoguesHealth, Agriculture & Inclusion
Former Professor & Head, Centre for Community Medicine, AIIMS, New Delhi
Public health & nutrition
An interaction with Dr. Karan Garg
Read the interactionBharat Pulse · Healthcare regulatory insights
Dated regulatory notes with official references and a separately identified TLGS perspective.
A Maharashtra FDA order brings prescription access and patient choice into the operating controls of hospital-linked pharmacy services.
Official order · reviewed 13 September 2026
Read the sourced insight →Current Maharashtra FDA portal guidance makes application-channel verification an important first step for new manufacturing and sales users.
Official portal guidance · reviewed 13 September 2026
Read the sourced insight →A central-government reply explains the public drug-alert process. For retail and e-pharmacy networks, the operating question is how an alert becomes a traceable, location-specific response.
Official parliamentary reply · reviewed 13 September 2026
Read the sourced insight →These are independent TLGS sector notes, not Tata 1mg statements or findings about a client. Review dates are not announcement dates.
Engage TLGS
Connect the right expertise with your next decision.
